CG Oncology Inc. Shines at American Urological Association Annual Meeting

In a remarkable display of scientific progress, CG Oncology Inc., a late-stage biopharmaceutical company based in Irvine, United States, has made headlines with its latest findings in the fight against bladder cancer. The company, which specializes in developing a potential bladder-sparing therapeutic, announced significant results for its lead product, cretostimogene grenadenorepvec, at the 2025 American Urological Association Annual Meeting.

Impressive Durability Data in High-Risk Bladder Cancer Patients

The Phase 3 BOND-003 Cohort C study showcased the durability of cretostimogene grenadenorepvec, with a 24-month complete response rate of 42.3% in high-risk non-muscle invasive bladder cancer (NMIBC) patients. This promising data highlights the potential of the therapy to offer a durable response in a patient population that is at a high risk of disease progression.

Key findings from the study include:

  • A 75.5% complete response rate at any time.
  • An impressive 97.3% of patients remained free from progression to muscle invasive disease at 24 months.
  • 91.6% of responders remained cystectomy-free at 24 months.
  • A median duration of response of 28 months, with the study ongoing.

Early Signals of Success in Cohort P

In addition to the Cohort C results, Cohort P demonstrated a 90.5% high-grade recurrence-free survival at both 3 and 9 months. This early signal of success further underscores the potential of cretostimogene grenadenorepvec as a promising treatment option for bladder cancer patients.

Safety Profile and Market Reaction

The treatment has shown an excellent safety profile, which is crucial for patient acceptance and widespread adoption. Following the announcement of these results, CG Oncology’s stock experienced a significant surge, with the share price jumping from $22.37 to $31.76, marking a +41.98% increase. This positive market reaction reflects investor confidence in the company’s potential to revolutionize bladder cancer treatment.

Looking Ahead

CG Oncology Inc. continues to operate in the medical sector of the United States, with its stock traded on the Nasdaq. The company’s focus on developing and commercializing innovative therapies for bladder cancer positions it as a key player in the healthcare sector. As the company moves forward, the promising results from the BOND-003 study will undoubtedly play a crucial role in shaping its future strategies and potential impact on patients’ lives.

In conclusion, CG Oncology Inc.’s announcement at the American Urological Association Annual Meeting has set a new benchmark in the treatment of bladder cancer. With its lead product showing significant promise in both efficacy and safety, the company is well-positioned to make a meaningful difference in the lives of patients and the broader healthcare landscape.